Author(s):
Vieira-Sousa, E ; Canhão, H ; Alves, P ; Rodrigues, AM ; Teixeira, F ; Tavares-Costa, J ; Bernardo, A ; Pimenta, S ; Pimentel-Santos, F ; Gomes, JL ; Aguiar, R ; Videira, T ; Pinto, P ; Catita, C ; Santos, H ; Borges, J ; Sequeira, G ; Ribeiro, C ; Teixeira, L ; Ávila-Ribeiro, P ; Martins, F ; Ribeiro, R ; Fonseca, JE
Date: 2018
Persistent ID: http://hdl.handle.net/10400.17/3035
Origin: Repositório do Centro Hospitalar de Lisboa Central, EPE
Subject(s): CHLC IMA; Antibodies, Monoclonal/administration & dosage; Arthritis, Psoriatic/drug therapy; Double-Blind Method; Drug Therapy, Combination; Enthesopathy/drug therapy; Finger Joint; Immunosuppressive Agents/administration & dosage; Methotrexate/administration & dosage; Toe Joint; Treatment Outcome
Description
The GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 24 weeks. Both clinical (dactylitis severity score and the Leeds dactylitis index) and imaging (high resolution magnetic resonance imaging), among others, were assessed as outcomes. The main objective of GO-DACT is to provide evidence to improve the treatment algorithm and care of psoriatic arthritis patients with active dactylitis. In this manuscript we describe the GO-DACT protocol and general concepts of the methodology of this trial.
